BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

944 related articles for article (PubMed ID: 27697638)

  • 1. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
    Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
    Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
    He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
    J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
    Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
    Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
    Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
    Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity.
    Singh N; Tiem M; Watkins R; Cho YK; Wang Y; Olsen T; Uehara H; Mamalis C; Luo L; Oakey Z; Ambati BK
    Blood; 2013 May; 121(20):4242-9. PubMed ID: 23476047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
    Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
    Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bee venom inhibits tumor angiogenesis and metastasis by inhibiting tyrosine phosphorylation of VEGFR-2 in LLC-tumor-bearing mice.
    Huh JE; Baek YH; Lee MH; Choi DY; Park DS; Lee JD
    Cancer Lett; 2010 Jun; 292(1):98-110. PubMed ID: 20188461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.
    Pavlakovic H; Becker J; Albuquerque R; Wilting J; Ambati J
    Ann N Y Acad Sci; 2010 Oct; 1207 Suppl 1(Suppl 1):E7-15. PubMed ID: 20961309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Vegfr3 gene therapy suppresses multi-organ metastasis in a mouse mammary cancer model.
    Shibata MA; Shibata E; Tanaka Y; Shiraoka C; Kondo Y
    Cancer Sci; 2020 Aug; 111(8):2837-2849. PubMed ID: 32539229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
    Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway.
    Huang B; Lu Y; Gui M; Guan J; Lin M; Zhao J; Mao Q; Lin J
    Biomed Pharmacother; 2021 May; 137():111331. PubMed ID: 33578235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.